Epstein Secrets

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

sh balance as of the Valuation Dale includes the cash proceeds from the most recent Series 5 round of financing (of approximately 539.5 million from IP Morgan Private Equity). which dosed recent to the Valuation Date. As of For the fiscal }emending December 31, 2008 2009 2010 Val.Dale 2011 2012 2013 2014 2015

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

sh balance as of the Valuation Dale includes the cash proceeds from the most recent Series 5 round of financing (of approximately 539.5 million from IP Morgan Private Equity). which dosed recent to the Valuation Date. As of For the fiscal }emending December 31, 2008 2009 2010 Val.Dale 2011 2012 2013 2014 2015

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

sh balance as of the Valuation Dale includes the cash proceeds from the most recent Series 5 round of financing (of approximately 539.5 million from IP Morgan Private Equity). which dosed recent to the Valuation Date. As of For the fiscal }emending December 31, 2008 2009 2010 Val.Dale 2011 2012 2013 2014 2015